Literature DB >> 12038871

Unlicensed and off-label drug use: issues and recommendations.

Sharon Conroy1.   

Abstract

Most adult patients would expect to receive only medicines which have been shown to be well tolerated, effective, and of a high quality. The licensing process to which most drugs are subjected gives the best assurance available that these criteria are met. However, every day, children are required to take medicines which are either not licensed, or are being used outside the terms of their license. Consequently, we cannot be sure that they meet the high standards we require for adult patients. This situation exists wherever children are treated across the world, and when they are in hospital or treated at home. The drugs involved are not obscure; they are routinely used drugs, and many are the mainstay of pediatric therapeutics. The terms 'unlicensed' and 'off-label' should not be taken to imply disapproval, nor incorrect or improper use of drugs, as such prescribing is a vital part of everyday pediatric drug therapy. It is essential because the gold-standard randomized clinical trials supporting adult medicine are often unavailable for children's treatments. Adequate information is not available to ensure that children have timely access to well tolerated and effective medicines with accurate, scientifically justified prescribing information. Many problems arise from this situation, including the lack of availability of appropriate pediatric drug formulations, poor prescribing information, and increased risk of medication errors and unanticipated adverse drug reactions. This situation is unacceptable. The US has taken the lead to change this situation by providing legislation and incentives to the pharmaceutical industry to perform pediatric clinical trials. Funding has been provided to set up research facilities where trials can be conducted by experienced pediatric investigators using imaginative, innovative, and noninvasive testing methods. The rest of the world should learn from these experiences and follow this lead to ensure that children have the same rights as adults to well tolerated and effective medicines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12038871     DOI: 10.2165/00128072-200204060-00002

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  32 in total

1.  Adverse drug reactions and the package insert.

Authors:  C J Coté
Journal:  Acta Paediatr       Date:  1999-09       Impact factor: 2.299

2.  Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use.

Authors:  P Impicciatore; I Choonara
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

3.  Birth of a formulary.

Authors:  P S Hull
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

4.  Unlicensed and off label drug use in neonates.

Authors:  S Conroy; J McIntyre; I Choonara
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-03       Impact factor: 5.747

5.  [The incidence of prescriptions without marketing product license in a neonatal intensive care unit].

Authors:  S Avenel; A Bomkratz; G Dassieu; J C Janaud; C Danan
Journal:  Arch Pediatr       Date:  2000-02       Impact factor: 1.180

6.  Unlicensed and off label drug use in paediatric wards: prospective study.

Authors:  S Turner; A Longworth; A J Nunn; I Choonara
Journal:  BMJ       Date:  1998-01-31

7.  Tenfold errors in administration of drug doses: a neglected iatrogenic disease in pediatrics.

Authors:  G Koren; Z Barzilay; M Greenwald
Journal:  Pediatrics       Date:  1986-06       Impact factor: 7.124

8.  Use of "off-label" and unlicensed drugs in paediatric intensive care unit.

Authors:  S Turner; A Gill; T Nunn; B Hewitt; I Choonara
Journal:  Lancet       Date:  1996-02-24       Impact factor: 79.321

9.  Pediatric drug therapy in the emergency department: does it meet FDA-approved prescribing guidelines?

Authors:  J P McKinzie; S W Wright; K D Wrenn
Journal:  Am J Emerg Med       Date:  1997-03       Impact factor: 2.469

10.  Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study.

Authors:  S Turner; A J Nunn; K Fielding; I Choonara
Journal:  Acta Paediatr       Date:  1999-09       Impact factor: 2.299

View more
  19 in total

1.  The trials and tribulations of doing drug research in children.

Authors:  Doreen Matsui; Charisse Kwan; Erin Steer; Michael J Rieder
Journal:  CMAJ       Date:  2003-11-11       Impact factor: 8.262

2.  Frontline ethical issues in pediatric clinical research: ethical and regulatory aspects of seven current bottlenecks in pediatric clinical research.

Authors:  Wim Pinxten; Herman Nys; Kris Dierickx
Journal:  Eur J Pediatr       Date:  2010-07-29       Impact factor: 3.183

3.  Where physicians look for information on drug prescribing for children.

Authors:  Doreen M Matsui; Mary Elizabeth Jardine; Erin Steer; Victoria Cukernik; Michael J Rieder
Journal:  Paediatr Child Health       Date:  2003-04       Impact factor: 2.253

4.  When do children convert from liquid antiretroviral to solid formulations?

Authors:  Vincent W Yeung; Ian C K Wong
Journal:  Pharm World Sci       Date:  2005-10

5.  Evaluation of unlicensed and off-label antiepileptic drugs prescribed to children: Brazilian Regulatory Agency versus FDA.

Authors:  Anna Paula de Sá Borges; Marília Silveira de Almeida Campos; Leonardo Régis Leira Pereira
Journal:  Int J Clin Pharm       Date:  2013-02-21

Review 6.  Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review.

Authors:  Joana Magalhães; António Teixeira Rodrigues; Fátima Roque; Adolfo Figueiras; Amílcar Falcão; Maria Teresa Herdeiro
Journal:  Eur J Clin Pharmacol       Date:  2014-10-16       Impact factor: 2.953

7.  Evaluating Solubility of Celecoxib in Age-Appropriate Fasted- and Fed-State Gastric and Intestinal Biorelevant Media Representative of Adult and Pediatric Patients: Implications on Future Pediatric Biopharmaceutical Classification System.

Authors:  Ramzi Shawahna; Ahed Zyoud; Aseel Haj-Yahia; Raheek Taya
Journal:  AAPS PharmSciTech       Date:  2021-03-01       Impact factor: 3.246

8.  Drug related problems and off-label drug treatment in children as seen at a drug information centre.

Authors:  Elin Kimland; Ulf Bergman; Synnöve Lindemalm; Ylva Böttiger
Journal:  Eur J Pediatr       Date:  2006-12-29       Impact factor: 3.183

9.  [Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management].

Authors:  B Messerer; G Grögl; W Stromer; W Jaksch
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

10.  Off-label drug use in a Pediatric Intensive Care Unit.

Authors:  S B Bavdekar; Pranjali A Sadawarte; Nithya J Gogtay; Surabhi S Jain; Sandhya Jadhav
Journal:  Indian J Pediatr       Date:  2009-11       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.